Share Name Share Symbol Market Type Share ISIN Share Description
Clinigen Group Plc LSE:CLIN London Ordinary Share GB00B89J2419 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  -14.50 -2.35% 602.50 634,533 16:35:08
Bid Price Offer Price High Price Low Price Open Price
601.50 604.00 621.50 600.50 612.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 504.30 22.60 10.30 58.5 801
Last Trade Time Trade Type Trade Size Trade Price Currency
17:46:34 O 433 618.995 GBX

Clinigen (CLIN) Latest News

More Clinigen News
Clinigen Investors    Clinigen Takeover Rumours

Clinigen (CLIN) Discussions and Chat

Clinigen Forums and Chat

Date Time Title Posts
29/7/202112:06Clinigen - solid looking growth stock200
24/2/202122:59Clinigen - Speciality Pharmaceuticals1,052

Add a New Thread

Clinigen (CLIN) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Clinigen trades in real-time

Clinigen (CLIN) Top Chat Posts

Clinigen Daily Update: Clinigen Group Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker CLIN. The last closing price for Clinigen was 617p.
Clinigen Group Plc has a 4 week average price of 579.50p and a 12 week average price of 560p.
The 1 year high share price is 881p while the 1 year low share price is currently 554p.
There are currently 132,898,771 shares in issue and the average daily traded volume is 794,687 shares. The market capitalisation of Clinigen Group Plc is £800,715,095.28.
whatja: It will be some time before there is a natural rise in the SP….12-24m of consistent delivery with no nasty surprises and hopefully some positive news on Proleukin. Trying to spot a bid candidate and then having a bid occur are two different things. It will be a candidate for a bid, but at what price and when is highly uncertain. I have my holding which is underwater at present….I am not going to commit more funds speculatively….but if business performance improves I may be tempted in a year or so.
whatja: Well a positively glowing outlook for 21/22 and 22/23. Is that a come and get me call out to PE? If delivered the share price should look better in 6 and 12m time. Looking to pay off around 130m of debt in next two years. Proleukin looking sickly….may not recover but also washing its face against the debt taken on to buy it and he amortisation of its cost…. Clin will survive a big write down in Proleukin if it is needed, but management should avoid future big deals on waning drugs.
ali47fish: tomps what's the gist of his message about clin?
tomps2: Stuart Widdowson mentions CLIN at 32:42 in the latest PIWORLD interview Watch the video here: Https:// Or listen to the podcast here: Https://
sphere25: It is proving to be a tough one. It looks like 9 pips is my lot as the price flirts with 590p, which conveniently enough is the VWAP (who says technicals and algos don't gravitate toward and work off particular marks? :-)). It is difficult trying to pick the bounce on these sorts, but the price action does show the level of apprehension here. I don't know the history, but clear skepticism toward management and analysts judging by the price moves (they often speak volumes) in a market that has been very forgiving to the near majority. If this was pre-covid, I wouldn't have a go because that type of warning wouldn't be forgiven easily, but seen as the world has experienced a left field event, the markets have given leeway - alot of leeway. The market hasn't just been forgiving to companies that have announced delays or small warnings, it has also bid up shares on placings or pre-announced placings (e.g. MAB...actually just add in that CARD today have cited a possible fund raise too and the market hasn't batted an eye lid at it either), and seen as it a form of bullish bullish (understatement?) climate, it is worth a go. Perhaps a bigger bounce will follow in time to come. Time will no doubt tell for longer term folk. Now to leave the screen a tad early and sit outside in the nice weather... or not to sit outside (hard to leave the booming markets!). Hmmm... All imo DYOR
sphere25: Nibbled a few on that break of 580p. The first spike back up above 570p (where the seller in size was sat) to test that key mark of 580p clearly wasn't the proper move as it was too sharp and fast and didn't give time for all the sellers to participate. It dropped back on participation, and the price then come back up to re-test that mark in a more measured (for CLIN) way, but with a material difference in what looks like sellers capitulating at 570p. Now we now have a breach of the intraday resistance with the price TRYING to rally back, currently at 589p. So a possible bounce here now (needs to clear 590p now for another bullish move), but if I'm wrong (not everything works and CLIN clearly isn't the easiest to trade), I'll stick a stop under that resistance of 580p and take a small loss. All imo DYOR
sphere25: Peculiar price action here. You would have thought the market was aware of the information in that update. Normally short delays due to Covid cause minimal movement in price in this market, and even if there is weakness, it usually gets bought up. They are suggesting that the demand will return: "Group remains confident that Proleukin demand will return and exceed pre-COVID levels in the future" This makes the price action here even more anomalous. Today's price move has abit of a capitulation type feel (it has been a while since that has been said, maybe some cobwebs to dust off - real rosy markets to blame) about it too so a possible bounce candidate. It's a very illiquid one with rapid price moves so caution very much needed. IF there is a bounce today, a break back above 580p could be the mark to watch. If not, then possibly one to keep a tabs on for a firmer bottom forming before a recovery bounce. Seller in size currently at 570p EDIT: Erratic lunges - price leapt above 570p to 585p in a flash, sellers in size then came in at 580p and then 575p. I'd want to see a more gradual strong trend rather than these types of moves - that was bonkers, I'd only switched tabs for a moment and came back and thought "what the hell, price was 570p" ha All imo DYOR
cousin jack: Marvel: They were fairly general comments such as “ Analysts also said Clinigen could be a potential takeover target. Bids have been launched for a series of healthcare companies recently, including UDG Healthcare and Vectura. Investec said the weakened share price “could represent an opportunity for cash rich private equity players, who are active in the pharma services arena” and Peel Hunt said there was an “increasing risk of a strategic takeover”.
adamb1978: Hi Cellars Yes, I had a look through the results this morning, but need a closer look later. Gut feel was that they were what I was expecting with a slight positive comment about current year growth Market forecasts are for 63p EPS this year growing to 87p in FY23 and I think those figures are very achievable. On that basis, I think £10-£12 share price is eminently achievable within a couple years. The de-gearing over the course of this year I think will help move the share price along, along with the general achievement of results. Adam
adamb1978: I dont think so (or certainly hope not!). The share price is just lacking near-term impetus but once we get into 2021 and leverage comes off and they start to trend to their stated growth targets I think you'll see the share price recover. I'm still looking for £12 within a couple years
Clinigen share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210729 18:46:44